These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33949178)

  • 1. Dyslipidemia and prevention of atherosclerotic cardiovascular disease in the elderly.
    Lucchi T
    Minerva Med; 2021 Dec; 112(6):804-816. PubMed ID: 33949178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dyslipidemias and statins: from guidelines to clinical practice. An updated review of the literature].
    Lucchi T; Vergani C
    G Ital Cardiol (Rome); 2014 Mar; 15(3):149-60. PubMed ID: 24770428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Clinical Guide to Combination Lipid-Lowering Therapy.
    Russell C; Sheth S; Jacoby D
    Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.
    Berman AN; Blankstein R
    Curr Cardiol Rep; 2019 Aug; 21(9):110. PubMed ID: 31378838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dislipidemia and lipid lowering drugs: from guidelines to clinical practice. An updated review of the literature.].
    Lucchi T; Cesari M; Vergani C
    Recenti Prog Med; 2020; 111(7):426-443. PubMed ID: 32658882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-lowering therapy: who can benefit?
    Lewis SJ
    Vasc Health Risk Manag; 2011; 7():525-34. PubMed ID: 21915170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chinese expert consensus on management of dyslipidemia in the elderly].
    Liu ML; Zhang ZF; Fu P; Ye YF; Guo F; Wang Q; He JJ; Li XW; Yan YH; Liao XF; Zhou XP; Tuo ZH; Wang Z;
    Zhonghua Nei Ke Za Zhi; 2022 Oct; 61(10):1095-1118. PubMed ID: 36207965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypolipidemic drugs in elderly subjects: Indications and limits.
    Gazzola K; Vigna GB
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1064-1070. PubMed ID: 27522161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Therapy of Dyslipidemia in the Elderly.
    Yandrapalli S; Gupta S; Andries G; Cooper HA; Aronow WS
    Drugs Aging; 2019 Apr; 36(4):321-340. PubMed ID: 30613912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the treatment of dyslipidemia.
    Sabatine MS
    Cleve Clin J Med; 2016 Mar; 83(3):181-6. PubMed ID: 26974988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-lowering therapy in patients 75 years and older: clinical priority or superfluous therapy?
    Phan BA; Bittner V
    Prog Cardiovasc Dis; 2014; 57(2):187-96. PubMed ID: 25216618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Status of cholesterol goal attainment for the primary and secondary prevention of atherosclerotic cardiovascular disease in dyslipidemia patients receiving lipid-lowering therapy: DYSIS-China subgroup analysis].
    Li Y; Zhao SP; Ye P; Yan XW; Mu YM; Wei YD; Hu DY;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Aug; 44(8):665-70. PubMed ID: 27545124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dyslipidemia Part 2: Review of Dyslipidemia Treatment in Patients With Noncoronary Vascular Disease.
    Gonzalez L; Helkin A; Gahtan V
    Vasc Endovascular Surg; 2016 Feb; 50(2):119-35. PubMed ID: 26983668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
    Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
    Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
    Handelsman Y; Shapiro MD
    Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.